Skip to main content

Table 2 Toxicity maximum grade per patient – attributable to treatment

From: Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy

Toxicity type Description Grade   
   1 2 3
BL101 Anemia 0 0 2
BL999 Blood and lymphatic system disorders - Other 1 0 0
CN108 Fatigue 3 0 0
CN109 Fever 2 0 0
CN121 Non-cardiac chest pain 1 0 0
GI121 Constipation 1 0 0
GI123 Diarrhea 1 0 0
GI124 Dry mouth 2 0 0
GI179 Nausea 2 1 0
GI210 Stomach pain 1 0 0
GI216 Vomiting 3 0 0
GI999 Gastrointestinal disorders - Other 1 0 0
IN171 Urinary tract infection 1 0 0
IV127 Lymphocyte count decreased 0 0 1
IV131 Platelet count decreased 0 1 1
ME999 Metabolism and nutrition disorders - Other 2 0 0
MU112 Generalized muscle weakness 1 0 0
MU999 Musculoskeletal and connective tissue disorder - Other 1 0 0
NE118 Dysgeusia 1 0 0
NE126 Headache 1 0 0
PU113 Cough 1 0 0
PU999 Respiratory, thoracic and mediastinal disorders - Other 1 0 0
VA102 Flushing 1 0 0
VA104 Hot flashes 1 0 0
TOTAL   29 2 4
Worst grade per patient across all types  
  Count Percentage
Mild - grade 1 as worst degree 5 45.45%
Moderate - grade 2 as worst degree 1 9.09%
Severe - grade 3 as worst degree 4 36.36%
Life threatening 1 9.09%